Thank you. Earlier today, Seer released financial results for the quarter and year ended December 31, 2025. If you've not received this news release or if you'd like to be added to the company's ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
Fourth quarter and full year 2025 revenue exceeded guidanceFRAMINGHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an ...
Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results